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Abstract
Among the natural compounds, terpenoids play an important role in the drug discovery process for tropical diseases. The
aim of the present work was to isolate antiprotozoal compounds from Ambrosia elatior and A. scabra. The sesquiterpene
lactone (STL) cumanin was isolated from A. elatior whereas two other STLs, psilostachyin and cordilin, and one sterol
glycoside, daucosterol, were isolated from A. scabra. Cumanin and cordilin were active against Trypanosoma cruzi
epimastigotes showing 50% inhibition concentrations (IC50) values of 12 mM and 26 mM, respectively. Moreover, these
compounds are active against bloodstrean trypomastigotes, regardless of the T. cruzi strain tested. Psilostachyin and
cumanin were also active against amastigote forms with IC50 values of 21 mM and 8 mM, respectively. By contrast,
daucosterol showed moderate activity on epimastigotes and trypomastigotes and was inactive against amastigote forms.
We also found that cumanin and psilostachyin exhibited an additive effect in their trypanocidal activity when these two
drugs were tested together. Cumanin has leishmanicidal activity with growth inhibition values greater than 80% at a
concentration of 5 mg/ml (19 mM), against both L. braziliensis and L. amazonensis promastigotes. In an in vivo model of T.
cruzi infection, cumanin was more active than benznidazole, producing an 8-fold reduction in parasitemia levels during the
acute phase of the infection compared with the control group, and more importantly, a reduction in mortality with 66% of
the animals surviving, in comparison with 100% mortality in the control group. Cumanin also showed nontoxic effects at the
doses assayed in vivo, as determined using markers of hepatic damage.
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Introduction
Natural products have been a major source of drugs mainly for
treating infectious diseases and cancer [1]. About 75% of anti-
infective drugs approved from 1981 to 2002 are derived from
natural sources. Many of them were isolated from plants and have
shown antiparasitic activity. The first antimalarial drug, quinine,
was isolated from Cinchona spp. and led to the development of
other antimalarial drugs such as chloroquine, which is currently in
use. More recently, the sesquiterpene lactone (STL) artemisinin
has been isolated from the Chinese plant Artemisia annua, which has
been used for over 2000 years to treat malaria. At present, this
natural compound and its derivatives are used for treating
chloroquine-resistant malaria.
Both Chagas disease and leishmaniasis are protozoan diseases
that cause significant morbidity and mortality in Latin America,
whereas leishmaniasis also worldwide. According to the World
Health Organization (WHO), they are considered, among others,
Neglected Tropical Diseases (NTDs) mainly affecting poor people
in developing countries [2]. These parasitoses are often forgotten
by governments and the pharmaceutical industry, due to economic
reasons and a relatively limited market. Therefore, the develop-
ment of new drugs for the treatment of these parasitic diseases
remains a highly desirable goal.
Chagas’ disease or American trypanosomiasis is caused by the
protozoan parasite Trypanosoma cruzi, which is transmitted by
blood-sucking insects. This parasitic disease affects 8 million
people, mostly in endemic areas of Latin America, but has now
spread to other continents [3]. Up to 30% of patients develop
heart failure and people usually die from sudden death caused by
arrhythmias. The chronic phase of the disease can cause damage
to the esophagus, colon or the autonomic nervous system in more
than 10% of patients. It is estimated that Chagas’ disease killed
more than 10,000 people in 2008 [3]. In Argentina, 1.5 to 2
million people are affected and it is estimated that 15 people die of
this parasitosis every week [4].
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Leishmaniasis is caused by kinetoplastids from the genus
Leishmania and is transmitted by sand flies. WHO estimates that
almost 12 million people worldwide are infected with Leishmania
spp. and 350 million are at risk of contracting this parasitic disease
[5]. Cutaneous leishmaniasis is endemic in Northern Argentina
covering an area of 500,000 km2 where it is common to find
people coinfected with T. cruzi and Leishmania sp. [6]. Its incidence
has increased during the last two decades mainly due to Leishmania
braziliensis [7]. The clinical manifestations of these parasitoses
depend on the Leishmania species involved, presenting three
different clinical forms: cutaneous, mucocutaneous and visceral
leishmaniasis.
Most of the drugs currently in use for the treatment of American
trypanosomiasis and leishmaniasis have severe drawbacks. The
available treatments for Chagas disease are limited to the
nitroaromatic compounds, benznidazole and nifurtimox, which
were released in the 1970s. Even though these two drugs are active
in the acute stage of infection, they are ineffective in the treatment
of the chronic phase. They have toxic side effects and are not
active against all T. cruzi strains [8]. The current antileishmanial
therapy includes the use of pentavalent antimonials, amphotericin
B, miltefosine or paromomycin, which have disadvantages in
terms of the route of administration, parasite resistance, cost,
teratogenic effects, length of treatment and toxicity [9]. Among the
natural compounds, terpenoids display a wide range of biological
activities such as anticancer and anti-inflammatory actions and are
effective against infective agents such as viruses, bacteria and
parasites [10,11]. Several terpenoids have been reported to have
trypanocidal and leishmanicidal activities [12–15]. Recent re-
search has shown the potential role of terpenoids as promising
compounds against neglected protozoan diseases such as Chagas’
disease and leishmaniasis [16,17]. An exhaustive and updated
revision has been recently performed by Schmidt and coworkers
[18]. These authors revised the antiprotozoal activities of the
major biogenetic subclassses of terpenes focusing on STLs,
diterpenes and triterpenes. Within the STLs, germacranolides,
guaianolides, xanthanolides and pseudoguaianolides, have exhib-
ited significant antiprotozoal activity, showing the potential of this
class of compounds [18].
In the last decades, Asteraceae has been regarded as a
promising family of plants because of the amount and variety of
active compounds produced by the secondary metabolism. STLs
and triterpenes isolated from this family have been reported as
having trypanocidal and leishmanicidal activities [16–18,19]. In
Argentina, the genus Ambrosia that belongs to this family is
represented by three species: A. tenuifolia, A. scabra and A. elatior.
Considering the limitations of current therapies for Chagas disease
and leishmaniasis and our previous promising findings on the
antiprotozoal activity of terpenoids from the genus Ambrosia [20–
23], the aim of the present work was to isolate further bioactive
compounds from A. elatior and A. scabra.
Materials and Methods
Plant material
The aerial parts of Ambrosia elatior L. (BAF 707) and Ambrosia
scabra Hook. & Arn. (Asteraceae) (BAF 711) were collected in
Buenos Aires Province, Argentina in May 2009. The botanical
identification was performed by Dr. Gustavo Giberti and a
voucher specimen of each species was deposited at the Museo de
Farmacobota´nica, Facultad de Farmacia y Bioquı´mica, Universi-
dad de Buenos Aires.
Parasites
Trypanosoma cruzi epimastigotes (RA and K98 strains) were
grown in a biphasic medium. Cultures were routinely maintained
by weekly passages at 28uC. T. cruzi bloodstream trypomastigotes
from RA and K98 strains [24] were obtained from infected CF1
mice by cardiac puncture at the peak of parasitemia on day 15
postinfection. Trypomastigotes were routinely maintained by
infecting 21-day-old CF1 mice. T. cruzi amastigotes were obtained
from cultured cells infected with tripomastigotes. Leishmania
braziliensis and Leishmania amazonensis promastigotes (MHOM/
BR/75/M2903 and MHOM/BR/75/M2269 strains, respective-
ly) were grown in liver infusion tryptose medium (LIT). Cultures
were routinely maintained by weekly passages at 26uC. Parasites
were passaged 24 or 48 h previous to the experiments.
Animal ethics statement
Inbred male C3H/HeN mice were nursed at the Microbiology
Department, Faculty of Medicine, University of Buenos Aires. All
procedures requiring animals were performed in agreement with
institutional guidelines and were approved by the Review Board of
Ethics of IDEHU, CONICET, and conducted in accordance with
the Guide for the Care and Use of Laboratory Animals of the
National Research Council of Argentina [25].
Plant extracts
Extraction of the aerial parts of A. elatior and A. scabra was done
by maceration with dichloromethane:methanol (1:1), as previously
described [22].
Fractionation of Ambrosia elatior extract
The organic extract of A. elatior (AE-OE) was fractionated by
column chromatography on Silica gel 60 with a gradient of
hexane, ethyl acetate and methanol. Nine fractions (F1AE–F9AE) of
500 ml each were collected and taken to dryness. Each fraction
was tested for trypanocidal activity on T. cruzi epimastigotes.
Fractions F5AE, F6AE and F7AE were taken with ethyl acetate and
Author Summary
In addition to the primary metabolism necessary for life,
plants have a secondary metabolism that generates
compounds, which aid in their growth and development.
A common role of secondary metabolites is defense
mechanisms to fight off animals, pest and pathogens.
Pharmacognosy takes advantage of the rich source of
compounds produced by plants, selecting and processing
natural products for medicinal use, resulting in a wide
range of anticancer, anti-inflammatory and anti-infective
drugs currently in use. Chagas disease and leishmaniasis
are parasitic diseases caused by protozoa transmitted by
sucking insects. According to the World Health Organiza-
tion (WHO) they are considered as Neglected Tropical
Diseases that are especially endemic in low-income
populations in developing countries. The drugs currently
in use were developed more than 50 years ago and have
severe drawbacks. The authors found that chemical
compounds called sesquiterpene lactones, obtained from
plants of the Asteraceae family, have anti-protozoan
activity against different parasite stages. The identified
compounds were also able to control parasitic infection in
mice without any toxic effects. Thus, these sesquiterpenes
lactones could be interesting chemical compounds having
pharmacological properties, whose chemical structure
could be modified leading to potent and safer drugs to
treat these parasitoses.
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afforded a crystalline compound named compound A, which was
assayed for trypanocidal and leishmanicidal activities.
Isolation of compounds from fraction F5AS of Ambrosia
scabra
Fractionation of organic extract of A. scabra has been previously
described [23]. A pure compound, compound B, was obtained
from fractions F5AS(70–74) by crystallization from ethyl acetate.
Compound C was obtained as a white crystalline precipitate from
fractions F5AS(75–77), while fractions F5AS(125–135) afforded a white
amorphous powder (compound D).
Compound identification
The structure elucidation of compounds A–D was performed by
proton nuclear magnetic resonance (1H NMR) and carbon NMR
(13C NMR) (Inova NMR spectrometer; Varian, Palo Alto, CA)
500 MHz in CDCl3 (for compounds A, B and C) and
CDCl3:CD3OD (8:2) (for compound D), heteronuclear single
quantum correlation (HSQC); heteronuclear multiple bond
correlation (HMBC); correlated spectroscopy (COSY); electron
impact-mass spectrometry (EI-MS) (Agilent 5973) and infrared
spectroscopy (Bruker FT-IR IFS25).
In vitro trypanocidal and leishmanicidal activity assay
Growth inhibition of T. cruzi epimastigotes and Leishmania spp.
promastigotes was evaluated by a [3H] thymidine uptake assay as
previously described [20]. Parasites were adjusted to a cell density
of 1.56106/ml and cultured in the presence of A. elatior organic
extract, the fractions and purified compounds for 72 h at final
concentrations ranging from 1 to 100 mg/ml. Benznidazole (5 to
20 mM; Roche) and Amphotericin B (0.27–1.6 mM; ICN) were
used as positive controls (data not shown). The percentage of
inhibition was calculated as 1002{[(cpm of treated parasites)/
(cpm of untreated parasites)]6100}.
The trypanocidal effect of the pure compounds was also tested
on bloodstream trypomastigotes of RA and K98 strains as
previously described [20]. Briefly, mouse blood containing
trypomastigotes was diluted in complete liver infusion tryptose
medium to adjust the parasite concentration to 1.56106/ml.
Parasites were seeded (150 ml/well) by duplicate into a 96-well
microplate, and 2 ml of each compound/well at different
concentrations or control drug (benznidazole) was added per well.
Plates were incubated for 24 h and the remaining live parasites
were counted on a hemocytometer. Results are expressed as [live
parasites in wells after compound treatment/live parasites in
untreated wells]6100.
To evaluate the effect of the compounds on intracellular forms
of T. cruzi, 96-well plates were seeded with nonphagocytic Vero
cells at 56103 per well in 100 mL of culture medium and were
incubated for 24 h at 37uC in a 5% CO2 atmosphere. Cells were
washed and infected with transfected blood trypomastigotes
expressing b-galactosidase [26] at a parasite/cell ratio of 10:1.
After 24 h of coculture, plates were washed twice with PBS to
remove unbound parasites and each pure compound was added at
different concentrations in 150 ml of fresh complete RPMI
medium without phenol red (Gibco, Rockville, MD). Controls
included infected untreated cells (100% infection control) and
uninfected cells (0% infection control). The assay was developed
by the addition of chlorophenolred-b-D-galactopyranoside
(CPRG) (100 mM) and 1% Nonidet P40, 5 days later. Plates were
then incubated for 4–6 h at 37uC and the absorbance was
measured at 595 nm in a microplate reader (Bio-Rad Laborato-
ries, Hercules, CA). Percentage inhibition was calculated as
100–{[(absorbance of treated infected cells)/(absorbance of
untreated infected cells)6100} and the IC50value was estimated.
Drug interaction
Compounds A and B were combined with each other, as well as
compound A and benznidazole, to evaluate a potential interaction
among them. Trypanocidal activity was evaluated on RA
epimastigotes by a [3H] thymidine uptake assay as previously
described [20]. The fractional inhibitory concentrations (FICs)
were calculated as the ratio of the IC50 of one compound in
combination and the IC50 of the compound alone. The FIC index
(FICI) for the two compounds was the FIC of compound A plus
the FIC of compound B. The fractional inhibitory concentration
index (FICI) was interpreted as follows: FICI#0.5 synergy,
FICI.4.0 antagonism, FICI = 0.5–4 addition [27].
In vitro cytotoxicity assay
Vero cells were assayed to determine viability by the MTT
method [22]. Cells (56105) were settled at a final volume of 150 ml
in a flat-bottom 96-well microplate and were cultured at 37uC in a
5% CO2 atmosphere in the absence or presence of increasing
concentrations of the pure compounds. After 24 h, 3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) was
added at a final concentration of 1.5 mg/ml. Plates were
incubated for 2 h at 37uC. The purple formazan crystals were
completely dissolved by adding 150 ml of ethanol and the
absorbance was detected at 595 nm in a microplate reader.
Results were calculated as the ratio between the optical density in
the presence and absence of the compound multiplied by 100.
In vivo trypanocidal activity of compound A
Groups of five C3H/HeN male mice (6 to 8 weeks old;
27.260.9 g) were infected with 500 bloodstream T. cruzi
trypomastigotes by the intraperitoneal route. Five days after
infection, the presence of circulating parasites was confirmed by
the microhematocrit method [23]. Mice were treated daily with
compound A or benznidazole (1 mg/kg of body weight/day) for
five consecutive days (days 5 to 10 postinfection) by the
intraperitoneal route. Drugs were resuspended in 0.1 M phosphate
buffered saline (PBS, pH 7.2), and this vehicle was also employed
as a negative control. Levels of parasitemia were monitored every
2 days in 5 ml of blood diluted 1:5 in lysis buffer (0.75% NH4Cl,
0.2% Tris, pH 7.2) by counting parasites in a Neubauer chamber.
The number of deaths was recorded daily.
In vivo toxicity
Groups of five C3H/HeN male uninfected mice were treated
with PBS or compound A as described above, in order to evaluate
the potential in vivo toxicity of the compound. On day 7 post
treatment, blood samples were collected by cardiac puncture.
Serum activities of alanine aminotransferase (ALT), aspartate
aminotransferase (AST) and lactate dehydrogenase (LDH) were
determined as markers of hepatic damage. Assays were carried out
by ultraviolet spectrophotometry following the specifications of the
kit’s manufacturer (Wiener Lab, Buenos Aires, Argentina).
Statistical analysis
The results are presented as mean6SEM. The level of statistical
significance was determined by using one-way analysis of variance
(ANOVA), with GraphPad Prism 5.0 software (GraphPad
Software Inc., San Diego, CA). Long rank test was used for
survival curves. Comparisons were referred to the control group. P
values of ,0.05 were considered significant.
Terpenoids with Antitrypanosomatids Activity
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Results
Fractionation of Ambrosia elatior organic extract
The dichloromethane:methanol organic extract (AE-OE) from
the aerial parts of Ambrosia elatior was evaluated in vitro against T.
cruzi epimastigotes. This extract was active with a growth
inhibition of 93.762.0% at a concentration of 100 mg/ml. The
extract fractionation by chromatographic techniques using Silica
gel 60 with a gradient of hexane, ethyl acetate and metanol yielded
nine fractions (F1AE to F9AE), which were assayed for their in vitro
trypanocidal activity on epimastigotes at 100, 10 and 1 mg/ml
(Table 1). The results of this experiment showed that at a
concentration of 10 mg/ml, fractions F5AE, F6AE and F7AE were
the most active with percentages of growth inhibition of
94.760.5%, 75.364.8% and 76.861.4%, respectively (Table 1).
A pure compound (compound A) was further isolated from
fractions F5AE, F6AE and F7AE. It was identified by spectroscopic
methods as the STL 1a,3b,4b,5b,8b,10b-3,4-dihydroxy-11(13)-
pseudoguaien-12,8-olide or cumanin (Figure 1).
Isolation of compounds from fraction F5AS of Ambrosia
scabra
An exhaustive search in the active fraction F5AS from A. scabra
resulted in the isolation of three other compounds, B, C and D.
The analyses of spectroscopic data allowed to identify compounds
B and C as the STLs (29R,3aS,6s,8s,8aR)-octahydro-8-hydroxy-
6,8-dimethyl-3-methylene-spiro[7H-cyclohepta[b]furan-7,29(59H)-
furan]-2,59(3H)-dione psilostachyin and its 5-epimer cordilin
or epipsilostachyin, respectively. Compound D was identified as
the sterol glycoside sitosterol-3-O-b-D-glucopyranoside or
daucosterol (Figure 1).
Inhibition of T. cruzi epimastigotes
We analyzed the antiparasitic activity of the isolated compounds
at different stages of Trypanosoma cruzi and Leishmania sp. The
results of the trypanocidal activity of cumanin, cordilin and
daucosterol on T. cruzi epimastigote forms are shown in Figure 2.
The STLs were active with 50% inhibition concentration (IC50)
values of 12 mM and 4 mM for cumanin, and 26 mM and 44 mM
for cordilin against RA and K98 epimastigotes, respectively.
Daucosterol exhibited lower activity with a growth inhibition of
40.762.8% at 100 mg/ml (174 mM).
Drug interaction by the isobologram analysis
The combinatory effect of the two most active STLs,
psilostachyin and cumanin, on epimastigotes of T. cruzi was
analyzed by an isobologram. The fractional inhibitory concentra-
tion index (FICI) was 0.9760.11 (Mean6SD) for the combination
of these drugs, indicating there is neither antagonism nor
synergism; however, an additive effect could be assessed in the
trypanocidal activity between cumanin and psilostachyin
(Figure 3). We neither found antagonism nor synergism
interaction between cumanin and benznidazole, the current
reference drug to treat Chagas disease (FICI: 0.9560.05)
(Mean6SD) (Figure 3).
Inhibition of T. cruzi trypomastigotes
The trypanocidal effect of the pure compounds was tested on
bloodstream trypomastigotes obtained from infected mice. Para-
sites were seeded into a 96-well microplate and different
concentrations of each compound were added to each well. After
24 h incubation, the remaining live parasites were counted on a
hemocytometer. In Figure 4 it can be appreciated that the two
STLs, cumanin and cordilin, showed activity against RA
trypomastigotes with IC50 values of 180 mM and 90 mM,
respectively. The sterol glycoside was active with an IC50 of
142 mM.
In order to analyze the relevance of the compounds in different
T. cruzi populations, K98 trypomastigotes were incubated in
the presence of cumanin, cordilin and daucosterol, showing
IC50 values of 170 mM, 83 mM and 184 mM, respectively
(Figure 4).
Inhibition of T. cruzi amastigotes
To analyze the effect of the compounds on the replicative forms,
Vero cells were infected with transfected trypomastigotes express-
ing the b-galactosidase gene. After 24 h incubation, all the
parasites outside the cells were removed by washing and different
concentrations of the compounds were added to the wells. Five
days later the cells were disrupted with detergent and b-
galactosidase activity was determined with chlorophenol red-b-
D-galactopyranoside, as a direct estimation of the number of
parasites. Since the effect of psilostachyin was not previously
reported, the four isolated compounds were included in the assay.
Figure 5 shows that cumanin and psilostachyin were able to
inhibit amastigote replication. Both STLs were active with
approximately 95% inhibition at 25 mg/ml, and IC50s of 8 mM
and 21 mM, respectively. Neither cordilin nor daucosterol were
active against the intracellular forms of T. cruzi.
Inhibition of L. braziliensis and L. amazonensis
promastigotes
After the observed effect of cumanin, psilostachyin, cordilin and
daucosterol on T. cruzi, we analyzed the inhibitory activity of these
compounds on Leishmania promastigotes. The IC50 values against
L. amazonensis were 3 mM, 10 mM and 55 mM, for cumanin,
psilostachyin and cordilin, respectively. We found that cumanin
revealed leishmanicidal activity with growth inhibition values
greater than 80% at a concentration of 5 mg/ml (19 mM), against
both L. braziliensis and L. amazonensis (Figure 6). Psilostachyin and
cordilin displayed high leishmanicidal activity against L. braziliensis
(82.867.8 and 83.0360.01% at a concentration of 1 mg/ml,
respectively).
These results showed that cumanin was active against the two
species reported as the main cause of tegumentary leishmaniosis in
Argentina: L. braziliensis and L.amazonensis [6].
Table 1. In vitro trypanocidal activity of organic extract and
fractions of Ambrosia elatior on RA epimastigotes of T. cruzi.
Extract/fractions % Growth Inhibition
100 mg/ml 10 mg/ml 1 mg/ml
AE-OE 93.762.0 35.160.5 8.863.1
F1AE 1.466.0 2.860.9 3.160.2
F2AE 93.660.7 34.561.8 33.563.0
F3AE 93.760.9 49.666.9 9.267.9
F4AE 96.260.3 37.561.5 8.369.5
F5AE 96.560.2 94.760.5 41.062.9
F6AE 91.863.1 75.364.8 31.465.5
F7AE 86.362.6 76.861.4 31.1614.1
F8AE 79.162.0 32.064.2 29.7611.0
F9AE 40.365.2 25.263.0 20.763.7
Results are expressed as mean 6 S.E.M. (n = 3).
doi:10.1371/journal.pntd.0002494.t001
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In vivo trypanocidal activity of cumanin
To analyze the effect of the active compounds in vivo, a group of
mice was inoculated with a deadly number of trypomastigotes of
the RA strain and parasitemia was determined 5 days after to
confirm the effectiveness of the infection. Mice were then treated
with cumanin or benznidazole, the drug currently used to treat
infected humans, for 5 consecutive days. Parasitemia and survival
were periodically recorded. Figure 7A shows how cumanin was
able to dramatically reduce the number of circulating parasites in
the acute phase of T. cruzi infection compared with the PBS-
treated control. When we analyzed the area under the parasitemia
curve (AUC) we observed an important decrease in the number of
Figure 1. Chemical structures of the sesquiterpene lactones cumanin, psilostachyin and cordilin and the sterol glycoside
daucosterol.
doi:10.1371/journal.pntd.0002494.g001
Figure 2. Inhibition of T. cruzi epimastigotes by cumanin, cordilin and daucosterol. Growth inhibition of parasites was evaluated by a [3H]
thymidine uptake assay. Epimastigotes of (A) RA and (B) K98 strain, were adjust at 1.56106/ml and cultured for 72 h at 28uC in the presence of the
compounds at a final concentration ranging from 100 - 1 mg/ml. The percentage of inhibition was calculated as 1002[(cpm of treated parasites)/(cpm
of untreated parasites)]6100. Values represent mean 6 SEM from three independent experiments carried out in triplicate.
doi:10.1371/journal.pntd.0002494.g002
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circulating parasites in cumanin treated mice comparing with
controls (AUC: 382 and 800, respectively). This protection was
more important at the peak of parasitemia, on day 22
postinfection, when control mice showed 8 times more parasites
than cumanin-treated ones (8.2 and 1.26107 parasites/ml,
respectively, p,0.01). As shown in Figure 7A, parasitemia values
were slightly higher than those obtained with benznidazole but no
significant differences were found between the two compounds.
The ability of cumanin to control infection was also reflected in
the significant survival of the treated mice, respect to the control
(p = 0.0086). Figure 7B shows the important reduction in mice
mortality observed in cumanin-treated mice, where 100% of PBS-
treated mice died between days 22 and 26 postinfection, while
66% of cumanin-treated mice survived the T. cruzi infection by the
end of the experiment on day 100 (not shown). Again, cumanin-
treated mice did not show any significant differences with respect
to those treated with the approved drug for this parasitosis.
In vivo toxicity assay
Hepatic toxicity of the STL was evaluated through the
determination of a panel of hepatic-linked enzyme markers.
Serum levels of AST, LDH and AST were measured at 7 days post
treatment. Table 2 shows that cumanin treated mice exhibited
similar levels of the analyzed enzymes to those of PBS-treated
control mice, suggesting that cumanin is not hepatotoxic in vivo at
the doses used.
Discussion
In a previous investigation we have reported the isolation of
STLs from Argentinean Ambrosia species, some of which have
shown significant trypanocidal and leishmanicidal activities [20–
22]. These promising results prompted us to continue with the
search for other antiprotozoal compounds from Ambrosia scabra and
its related species, A. elatior.
The organic extract of A. elatior showed significant activity
against T. cruzi, being able to inhibit 94% of epimastigote growth
at a concentration of 100 mg/ml. When this extract was
chromatographed on a Silica gel column, 9 final fractions (F1AE–
F9AE) were obtained. Fractions F5AE, F6AE and F7AE displayed the
highest trypanocidal activity against the non-infective form of T.
cruzi and afforded compound A. The structural elucidation of this
Figure 3. Isobologram describing the effect of the combination of (A) cumanin and psilostachyin and, (B) cumanine and
benznidazole, on epimastigotes of T. cruzi. Growth inhibition of epimastigotes was evaluated by a [3H] thymidine uptake assay. RA
epimastigotes were cultured for 72 h in the presence of different combinations of both compounds ranging from 0–5 mg/ml. The fractional inhibitory
concentrations of drugs (FIC) were calculated for each point, and an isobologram was plotted. The fractional inhibitory concentration index (FICI) was
interpreted as follows: FICI#0.5 synergy, FICI.4.0 antagonism, FICI = 0.5–4 addition.
doi:10.1371/journal.pntd.0002494.g003
Figure 4. Effect of cumanin, cordilin and daucosterol against T. cruzi trypomastigotes. Bloodstream trypomastigotes diluted at 1.56106/ml
in complete liver infusion tryptose medium, were seeded by duplicate in the presence of different concentration of each compound (0–376 mM, 0–
375 mM and 0–174 mM, for cumanin, cordilin and daucosterol, respectively) and incubated at 4uC for 24 h. The remaining live parasites of (A) RA
strain, and (B) K98 strain, in each sample was determined in 5 ml of cell suspension diluted 1/5 in lysis buffer (0.75% NH4Cl, 0.2% Tris, pH 7.2) and
counted in a Neubauer chamber. Values represent mean 6 SEM from three independent experiments carried out in duplicate.
doi:10.1371/journal.pntd.0002494.g004
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substance was based on the analysis of its spectral data and was
identified as cumanin, which has been previously reported in
Ambrosia artemisiifolia [28] and Ambrosia cumanensis [29].
We recently found that the F5AS fraction of the organic extract
of A. scabra was very active against T. cruzi. From F5AS fraction we
isolated the STL psilostachyin C, whose anti-epimastigote and
anti-trypomastigote activity had been previously reported [22]. In
this manuscript we report that further isolation steps from A. scabra
fraction F5AS yielded other three compounds (B, C, D).
Compounds B and C were identified as the STLs, psilostachyin
and cordilin, respectively, and compound D as daucosterol. The
identification of all these compounds was performed by analysis of
their spectral data. Psilostachyin had been previously isolated from
A. tenuifolia by our group [20]; however, this is the first report of its
presence in A. scabra, and the first time the isolation of cordilin and
daucosterol from A. scabra has been reported. Psilostachyin and
cordilin are diasteroisomers that only differ in the spatial
configuration of the hydroxyl and methyl groups on C-5
(Figure 1).
T. cruzi is genetically highly diverse [30]. While RA, belonging
to TcII-DTUs, is a highly virulent pantropic/reticulotropic strain,
K98 (TcI) is a low virulence myotropic strain [31]. In order to
analyze the relevance of cumanin, cordilin and daucosterol in
different T. cruzi populations, K98 and RA strains were evaluated
for their trypanocidal activity. Even though the epimastigote stage
of the parasite is non-infective, it is easy to cultivate and therefore,
it is useful for a preliminary screening test [32]. Cumanin exerted
significant in vitro trypanocidal activity against this parasite form,
showing an IC50 value 12 mM and 4 mM for RA and K98 strains.
Cordilin was less active with an IC50 26 mM and 44 mM, for the
two strain analyzed. Daucosterol displayed even lower trypanoci-
dal activity. However, in the search for new potential trypanocidal
candidates, it is necessary to analyze the activity of the compounds
on the infective forms of the parasite. Consequently, cumanin,
Figure 5. Inhibition of T. cruzi amastigotes by cumanin, psilostachyin, cordilin and daucosterol. Vero cells (56103 p/well) were seeded in
a 96 well plates and infected 24 h later with transfected trypomastigotes expressing beta-galactosidase at a parasite cell ratio 10:1. After 24 h of
coculture, plates were washed and drug compounds were added at 0–94 mM, 0–96 mM, 0–96 mM and 0–43 mM, for cumanin, psilostachyin, cordilin,
and daucosterol, respectively, in 150 ml of RPMI medium without phenol red. On day 6 p.i., the assays were developed by addition of CPRG (100 mM)
and Nonidet P-40 (1%). Plates were incubated for 4–6 h at 37uC and quantitated at 570 nm. Controls included infected untreated cells (100%
infection control). The percentage of inhibition was calculated as 1002{[(Absorbance of treated infected cells)/(Absorbance of untreated infected
cells)]6100}.
doi:10.1371/journal.pntd.0002494.g005
Figure 6. Inhibition of Leishmania promastigotes grown by cordilin, psilostachyin, cumanin and daucosterol. Promastigotes of (A) L.
amazonensis and (B) L. braziliensis, were adjust at 1.56106/ml and cultured for 72 h at 26uC in the presence of 1–100 mg/ml of the compounds. [3H]
thymidine was added for the last 16 h of culture. The percentage of inhibition was calculated as 1002[(cpm of treated parasites)/(cpm of untreated
parasites)]6100. Result is representative of two independent experiments carried out in triplicate.
doi:10.1371/journal.pntd.0002494.g006
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cordilin and daucosterol were tested against trypomastigotes and
all the isolated compounds were evaluated against intracellular
amastigotes, including psilostachyin that had not been previously
evaluated against this parasite form [20]. Cordilin and cumanin
showed low activity on trypomastigotes (IC50 = 89 mM and
180 mM, respectively. The two STLs psilostachyin and cumanin
inhibited the growth of the intracellular forms of T. cruzi with
IC50s values of 21 mM and 8 mM, respectively. Cordilin and
daucosterol did not display any activity against amastigotes.
The fact that cumanin is active against amastigotes is of
particular interest, since the DNDi organization prioritizes the
development of drugs that are useful during the indeterminate and
chronic phases of the infection where parasites remain intracellular
[33]. The ability of compounds to inhibit the intracellular growth
of T. cruzi amastigotes is a more rigorous and relevant test of anti-
T. cruzi activity, as it is applied to a stage which is the predominant
and replicative form in mammals cells. The impairment of
amastigotes replication upon cumanin treatment could lead to a
reduction in tripomastigotes release from the cells and the
subsequent low parasitemia observed in mice.
Nowadays, the association of compounds could be an interest-
ing strategy for the control of Chagas disease. Thus, psilostachyin
and cumanin were tested together on epimastigotes to assess their
possible interaction. An additive effect was observed between these
two compounds.
Considering the incidence of the Leishmania spp. in South
America and the existence of patients co-infected with these
parasites and T. cruzi [34–36], the effect of the four compounds on
L. braziliensis and L. amazonensis promastigotes was also evaluated.
Cumanin, psilostachyin and cordilin revealed significant leishma-
nicidal activiy against both L. amazonenzis and L. brazilensis, while
daucosterol leishmanicidal activity was lower.
Trypanocidal activity of STL is highly influenced by stereo-
chemical or structural differences [37]. Schmidt et al. [38]
demonstrated that the STL helenalin was more active against T.
cruzi and T. b. rhodesiense than its diasteroisomer mexicanin, which
differs from the former only in the spatial orientation of an OH
group. In the case of the two epimeric STLs isolated from A. scabra,
cordilin and psilostachyin, the behavior of the two compounds
against non-infective and infective forms of T. cruzi was very
different. We have previously reported that psilostachyin is very
active against epimastigotes and trypomastigotes showing IC50
values of 4 mM and 3 mM, respectively [20]. Those values
compared with the results herein reported for cordilin with values
of 26 mM (epimastigotes) and 89 mM (trypomastigotes) signal that
psilostachyin is more active than cordilin. In the present study, we
have also demonstrated that psilostachyin is more active than its 5-
epimer on the intracellular form of the parasite. Thus, these results
support the fact that stereochemistry plays an important role in the
biological activity.
The administration of cumanin to T. cruzi-infected mice (1 mg/
kg/day) produced a significant reduction in parasitemia levels,
even lower than that produced by benznidazole, when compared
with PBS-treated control mice. An 8-fold reduction in parasitemia
levels was observed on day 22 postinfection compared with
control. Moreover, cumanin was able to reduce the number of
parasites during the whole course of the infection. More
importantly, 66% of the mice survived the deadly challenge with
trypomastigotes while only 20% of benznidazole-treated mice
survived, compared with 100% mortality in the PBS-treated mice
group. It should be noted that the dosis of 1 mg/kg/day used was
irrespective of cumanin and benznidazole IC50 values.
Interestingly, cumanin is more active on intracellular amasti-
gotes than on free trypomastigotes, which is not the case for
psylostachyin, since it is very active in both stages (Figure 5 and
reference [20]). This phenomenon could be attributed to the fact
that cumanin differently affects both parasite stages somehow
interacting in different metabolic pathways that deserve to be
further investigated. An alternative hypothesis suggesting that
cumanin affects both parasite stages similarly as well as the cells
Figure 7. In vivo trypanocidal activity of cumanin: parasitemia levels (A) and survival curve (B) during the acute infection period.
C3H/HeN female mice infected with 500 trypomastigotes were treated daily, by intraperitoneal route, with PBS, cumanin or benznidazole (1 mg/kg of
body weight/day), starting on day 5 postinfection. Levels of parasitemia were monitored every 2 days in 5 ml of fresh blood from the tail vein, by
counting parasites in a Neubauer chamber. The number of dead mice was recorded daily. Results are representative of three independent
experiments.
doi:10.1371/journal.pntd.0002494.g007
Table 2. Serum levels of hepatic enzymes in mice at 7 days
after treatment with cumanin and PBS.
LDH (IU/L) AST (IU/L) ALT (IU/L)
Cumanin 38.7621.5 4.861.7 11.161.8
PBS 45.764.4 9.763.2 10.363.5
Results are expressed as mean 6 S.E.M. (n = 5).
doi:10.1371/journal.pntd.0002494.t002
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infected by amastigotes, consequently killing the cell host and
parasites, cannot be sustained since cumanin showed to be
nontoxic for non-infected cells at the concentration used (Table 2).
The determination of in vitro and in vivo toxicity is a very
important point in a drug discovery process [17]. Cumanin and
cordilin displayed low cytotoxicity on Vero cell line at concentra-
tions of up to 100 mg/ml (data not shown). Moreover, cumanin-
treated mice (non-infected) exhibited similar serum levels of
hepatic-linked enzyme markers than those in the PBS-treated
control mice (Table 2). Thus, by using in vitro and in vivo toxicity
assays, we demonstrated the non-toxic effect of cumanin at the
doses used. These results are in agreement with those reported by
Lastra et al. [39], who found that cumanin produces low
cytotoxicity on peritoneal murine macrophages.
As it was mentioned in the introduction section, different types
of terpenoid compounds have shown to display antiprotozoal
activity [18,40], and among them, several STLs having an a,b-
unsaturated-c-lactone moiety have been reported to show
trypanocidal and leishmanicidal activities [18,41,42]. Thus, the
STLs psilostachyin and cumanin can be considered interesting
lead molecules for the development of drugs for Chagas’ disease.
Variability in the outcome and morbidity of T. cruzi infection
might be associated, at least in part, with the complex population
structure of the parasite. Taking this into account, the fact that
cumanin shows high activity at different stages and strains of T.
cruzi highlights the importance of searching new drugs against
Chagas disease. In addition, the leishmanicidal activity shown by
these compounds in a preliminary assay could be an interesting
fact to consider, since the endemic areas of Chagas disease and
leishmaniasis usually overlap in Latin America and co-infected
patients have been reported [34–36].
Despite the advances in the biology of protozoan parasites like
T. cruzi and Leishmania sp., the discovery and development of safer
drugs to treat American trypanosomiasis and/or leishmaniasis still
constitute a challenge. The results presented in this work
demonstrate that terpenoids, particularly STLs, are an interesting
group of natural compounds that could become good candidates
for antiprotozoal chemotherapy. Further studies involving the
evaluation of different targets will be useful to understand the
mechanisms of action of the isolated STLs.
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